The role of transcription factor Runx2 in tumor infiltrating T cells
Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector function of transferred...
Gespeichert in:
| Veröffentlicht in: | Journal for immunotherapy of cancer 2013-11, Vol.1 (S1), p.P23-P23, Article P23 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | P23 |
|---|---|
| container_issue | S1 |
| container_start_page | P23 |
| container_title | Journal for immunotherapy of cancer |
| container_volume | 1 |
| creator | Mbofung, Rina Peng, Weiyi Liu, Chengwen Xu, Chunyu Malu, Shruti Yang, Yan Ma, Wencai Wang, Zhiqiang Overwijk, Willem Davis, Eric Lee, Brendan Hwu, Patrick |
| description | Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector function of transferred T cells influenced by the immunosuppressive tumor microenvironment. In order to identify pathways which may contribute to this observation, we used a murine ACT model in which mice bearing established B16 tumors were treated with Pmel T cells which recognize the melanoma antigen gp100 in the context of H-2Db. Pmel T cells were recovered on day 6 and 13, after transfer, from the tumor and spleen of treated mice and their gene expression patterns were compared. We found that 720 genes were differentially expressed by T cells recovered from the tumor site compared to those recovered from the spleen. Amongst the differentially expressed genes were several transcription factors, including Runx2, Rora, E2F1 and Tcf7. After an initial in vivo screen, Runx2 overexpressing Pmels conferred a worse antitumor effect when compared to the control Pmels (median tumor size 30.7 vs 20.7 mm2 respectively on day 7 after T cell transfer, p |
| doi_str_mv | 10.1186/2051-1426-1-S1-P23 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3990955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638098272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1703-dd319965ce0bfe465e7cf8e845599cb48a184a64b02246c46bc0ba91d29f2ec3</originalsourceid><addsrcrecordid>eNpVkEtLAzEUhYMoWGr_gKuA69G8Jk02glStQkGxsw-ZTNKmTJOazIj-e6e0FF3d1-HcwwfANUa3GAt-R1CJC8wIL3CxxMU7oWdgdFqe_-kvwSTnDUIII0qFECPwWK0tTLG1MDrYJR2ySX7X-Rig06aLCX704ZtAH2DXb4fRB-fbQdj5sIIVNLZt8xW4cLrNdnKsY1A9P1Wzl2LxNn-dPSwKg6eIFk1DsZS8NBbVzjJe2qlxwgpWllKamgmNBdOc1YgQxg3jtUG1lrgh0hFr6BjcH2x3fb21jbFhyNGqXfJbnX5U1F79vwS_Vqv4paiUSJblYHBzNEjxs7e5U5vYpzBEVoRTgaQgUzKoyEFlUsw5WXf6gJHaA1d7nmrPU2G1xGoATn8BdzV0HA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638098272</pqid></control><display><type>article</type><title>The role of transcription factor Runx2 in tumor infiltrating T cells</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mbofung, Rina ; Peng, Weiyi ; Liu, Chengwen ; Xu, Chunyu ; Malu, Shruti ; Yang, Yan ; Ma, Wencai ; Wang, Zhiqiang ; Overwijk, Willem ; Davis, Eric ; Lee, Brendan ; Hwu, Patrick</creator><creatorcontrib>Mbofung, Rina ; Peng, Weiyi ; Liu, Chengwen ; Xu, Chunyu ; Malu, Shruti ; Yang, Yan ; Ma, Wencai ; Wang, Zhiqiang ; Overwijk, Willem ; Davis, Eric ; Lee, Brendan ; Hwu, Patrick</creatorcontrib><description>Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector function of transferred T cells influenced by the immunosuppressive tumor microenvironment. In order to identify pathways which may contribute to this observation, we used a murine ACT model in which mice bearing established B16 tumors were treated with Pmel T cells which recognize the melanoma antigen gp100 in the context of H-2Db. Pmel T cells were recovered on day 6 and 13, after transfer, from the tumor and spleen of treated mice and their gene expression patterns were compared. We found that 720 genes were differentially expressed by T cells recovered from the tumor site compared to those recovered from the spleen. Amongst the differentially expressed genes were several transcription factors, including Runx2, Rora, E2F1 and Tcf7. After an initial in vivo screen, Runx2 overexpressing Pmels conferred a worse antitumor effect when compared to the control Pmels (median tumor size 30.7 vs 20.7 mm2 respectively on day 7 after T cell transfer, p<0.05). We also found fewer numbers of circulating Pmels in mice that received Runx2 overexpressing Pmels when compared to mice that received control Pmels. In addition, there was decreased accumulation of Runx2 overexpressing Pmels at the tumor site when compared to the control Pmel (Median luciferase output of 2.0X107 vs 9.0X107 photons/s/cm2/sr, respectively on day 6 after T cell transfer, p value =0.042). To further interrogate the role of Runx2 in T cells, we assessed the production of IFN-γ after stimulation in vitro with either plate bound anti-CD3 or gp100 expressing tumor cells. We found that IFN-γ production was comparable between Runx2 overexpressing Pmels and control Pmels after anti-CD3 stimulation. However, IFN-γ production was impaired in Runx2 overexpressing Pmels upon stimulation with tumor cells. Furthermore, in vitro characterization also revealed that Runx2 overexpressing Pmels have decreased proliferation and display an apoptotic phenotype. Taken together, our studies suggest that Runx2 regulates apoptosis, proliferation and IFN-γ production in tumor reactive T cells. Further studies to mechanistically understand these findings are ongoing.</description><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1186/2051-1426-1-S1-P23</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Gene expression ; Immunotherapy ; Lymphocytes ; Melanoma ; Poster Presentation</subject><ispartof>Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P23-P23, Article P23</ispartof><rights>2013 Mbofung et al; licensee BioMed Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2013 Mbofung et al; licensee BioMed Central Ltd. 2013 Mbofung et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990955/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990955/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids></links><search><creatorcontrib>Mbofung, Rina</creatorcontrib><creatorcontrib>Peng, Weiyi</creatorcontrib><creatorcontrib>Liu, Chengwen</creatorcontrib><creatorcontrib>Xu, Chunyu</creatorcontrib><creatorcontrib>Malu, Shruti</creatorcontrib><creatorcontrib>Yang, Yan</creatorcontrib><creatorcontrib>Ma, Wencai</creatorcontrib><creatorcontrib>Wang, Zhiqiang</creatorcontrib><creatorcontrib>Overwijk, Willem</creatorcontrib><creatorcontrib>Davis, Eric</creatorcontrib><creatorcontrib>Lee, Brendan</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><title>The role of transcription factor Runx2 in tumor infiltrating T cells</title><title>Journal for immunotherapy of cancer</title><description>Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector function of transferred T cells influenced by the immunosuppressive tumor microenvironment. In order to identify pathways which may contribute to this observation, we used a murine ACT model in which mice bearing established B16 tumors were treated with Pmel T cells which recognize the melanoma antigen gp100 in the context of H-2Db. Pmel T cells were recovered on day 6 and 13, after transfer, from the tumor and spleen of treated mice and their gene expression patterns were compared. We found that 720 genes were differentially expressed by T cells recovered from the tumor site compared to those recovered from the spleen. Amongst the differentially expressed genes were several transcription factors, including Runx2, Rora, E2F1 and Tcf7. After an initial in vivo screen, Runx2 overexpressing Pmels conferred a worse antitumor effect when compared to the control Pmels (median tumor size 30.7 vs 20.7 mm2 respectively on day 7 after T cell transfer, p<0.05). We also found fewer numbers of circulating Pmels in mice that received Runx2 overexpressing Pmels when compared to mice that received control Pmels. In addition, there was decreased accumulation of Runx2 overexpressing Pmels at the tumor site when compared to the control Pmel (Median luciferase output of 2.0X107 vs 9.0X107 photons/s/cm2/sr, respectively on day 6 after T cell transfer, p value =0.042). To further interrogate the role of Runx2 in T cells, we assessed the production of IFN-γ after stimulation in vitro with either plate bound anti-CD3 or gp100 expressing tumor cells. We found that IFN-γ production was comparable between Runx2 overexpressing Pmels and control Pmels after anti-CD3 stimulation. However, IFN-γ production was impaired in Runx2 overexpressing Pmels upon stimulation with tumor cells. Furthermore, in vitro characterization also revealed that Runx2 overexpressing Pmels have decreased proliferation and display an apoptotic phenotype. Taken together, our studies suggest that Runx2 regulates apoptosis, proliferation and IFN-γ production in tumor reactive T cells. Further studies to mechanistically understand these findings are ongoing.</description><subject>Gene expression</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Melanoma</subject><subject>Poster Presentation</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkEtLAzEUhYMoWGr_gKuA69G8Jk02glStQkGxsw-ZTNKmTJOazIj-e6e0FF3d1-HcwwfANUa3GAt-R1CJC8wIL3CxxMU7oWdgdFqe_-kvwSTnDUIII0qFECPwWK0tTLG1MDrYJR2ySX7X-Rig06aLCX704ZtAH2DXb4fRB-fbQdj5sIIVNLZt8xW4cLrNdnKsY1A9P1Wzl2LxNn-dPSwKg6eIFk1DsZS8NBbVzjJe2qlxwgpWllKamgmNBdOc1YgQxg3jtUG1lrgh0hFr6BjcH2x3fb21jbFhyNGqXfJbnX5U1F79vwS_Vqv4paiUSJblYHBzNEjxs7e5U5vYpzBEVoRTgaQgUzKoyEFlUsw5WXf6gJHaA1d7nmrPU2G1xGoATn8BdzV0HA</recordid><startdate>20131107</startdate><enddate>20131107</enddate><creator>Mbofung, Rina</creator><creator>Peng, Weiyi</creator><creator>Liu, Chengwen</creator><creator>Xu, Chunyu</creator><creator>Malu, Shruti</creator><creator>Yang, Yan</creator><creator>Ma, Wencai</creator><creator>Wang, Zhiqiang</creator><creator>Overwijk, Willem</creator><creator>Davis, Eric</creator><creator>Lee, Brendan</creator><creator>Hwu, Patrick</creator><general>BMJ Publishing Group LTD</general><general>BioMed Central</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20131107</creationdate><title>The role of transcription factor Runx2 in tumor infiltrating T cells</title><author>Mbofung, Rina ; Peng, Weiyi ; Liu, Chengwen ; Xu, Chunyu ; Malu, Shruti ; Yang, Yan ; Ma, Wencai ; Wang, Zhiqiang ; Overwijk, Willem ; Davis, Eric ; Lee, Brendan ; Hwu, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1703-dd319965ce0bfe465e7cf8e845599cb48a184a64b02246c46bc0ba91d29f2ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Gene expression</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Melanoma</topic><topic>Poster Presentation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mbofung, Rina</creatorcontrib><creatorcontrib>Peng, Weiyi</creatorcontrib><creatorcontrib>Liu, Chengwen</creatorcontrib><creatorcontrib>Xu, Chunyu</creatorcontrib><creatorcontrib>Malu, Shruti</creatorcontrib><creatorcontrib>Yang, Yan</creatorcontrib><creatorcontrib>Ma, Wencai</creatorcontrib><creatorcontrib>Wang, Zhiqiang</creatorcontrib><creatorcontrib>Overwijk, Willem</creatorcontrib><creatorcontrib>Davis, Eric</creatorcontrib><creatorcontrib>Lee, Brendan</creatorcontrib><creatorcontrib>Hwu, Patrick</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mbofung, Rina</au><au>Peng, Weiyi</au><au>Liu, Chengwen</au><au>Xu, Chunyu</au><au>Malu, Shruti</au><au>Yang, Yan</au><au>Ma, Wencai</au><au>Wang, Zhiqiang</au><au>Overwijk, Willem</au><au>Davis, Eric</au><au>Lee, Brendan</au><au>Hwu, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of transcription factor Runx2 in tumor infiltrating T cells</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><date>2013-11-07</date><risdate>2013</risdate><volume>1</volume><issue>S1</issue><spage>P23</spage><epage>P23</epage><pages>P23-P23</pages><artnum>P23</artnum><issn>2051-1426</issn><eissn>2051-1426</eissn><abstract>Adoptive T cell therapy (ACT) is a promising treatment for melanoma patients with a clinical response rate of about 50%. However, half of patients treated do not respond to this therapy, underlining the need for improvement . One of the limitations of ACT is the poor effector function of transferred T cells influenced by the immunosuppressive tumor microenvironment. In order to identify pathways which may contribute to this observation, we used a murine ACT model in which mice bearing established B16 tumors were treated with Pmel T cells which recognize the melanoma antigen gp100 in the context of H-2Db. Pmel T cells were recovered on day 6 and 13, after transfer, from the tumor and spleen of treated mice and their gene expression patterns were compared. We found that 720 genes were differentially expressed by T cells recovered from the tumor site compared to those recovered from the spleen. Amongst the differentially expressed genes were several transcription factors, including Runx2, Rora, E2F1 and Tcf7. After an initial in vivo screen, Runx2 overexpressing Pmels conferred a worse antitumor effect when compared to the control Pmels (median tumor size 30.7 vs 20.7 mm2 respectively on day 7 after T cell transfer, p<0.05). We also found fewer numbers of circulating Pmels in mice that received Runx2 overexpressing Pmels when compared to mice that received control Pmels. In addition, there was decreased accumulation of Runx2 overexpressing Pmels at the tumor site when compared to the control Pmel (Median luciferase output of 2.0X107 vs 9.0X107 photons/s/cm2/sr, respectively on day 6 after T cell transfer, p value =0.042). To further interrogate the role of Runx2 in T cells, we assessed the production of IFN-γ after stimulation in vitro with either plate bound anti-CD3 or gp100 expressing tumor cells. We found that IFN-γ production was comparable between Runx2 overexpressing Pmels and control Pmels after anti-CD3 stimulation. However, IFN-γ production was impaired in Runx2 overexpressing Pmels upon stimulation with tumor cells. Furthermore, in vitro characterization also revealed that Runx2 overexpressing Pmels have decreased proliferation and display an apoptotic phenotype. Taken together, our studies suggest that Runx2 regulates apoptosis, proliferation and IFN-γ production in tumor reactive T cells. Further studies to mechanistically understand these findings are ongoing.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1186/2051-1426-1-S1-P23</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2051-1426 |
| ispartof | Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P23-P23, Article P23 |
| issn | 2051-1426 2051-1426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3990955 |
| source | BMJ Open Access Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Gene expression Immunotherapy Lymphocytes Melanoma Poster Presentation |
| title | The role of transcription factor Runx2 in tumor infiltrating T cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A10%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20transcription%20factor%20Runx2%20in%20tumor%20infiltrating%20T%20cells&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Mbofung,%20Rina&rft.date=2013-11-07&rft.volume=1&rft.issue=S1&rft.spage=P23&rft.epage=P23&rft.pages=P23-P23&rft.artnum=P23&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1186/2051-1426-1-S1-P23&rft_dat=%3Cproquest_pubme%3E2638098272%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638098272&rft_id=info:pmid/&rfr_iscdi=true |